AstraZeneca’s Susan Galbraith To Lead Its Entire Cancer R&D

Takes on José Baselga’s Role

After more that 10 years at the firm, Susan Galbraith has taken on an expanded role heading up oncology R&D at AstraZeneca.

Following the death of José Baselga earlier this year, AstraZeneca has announced that Susan Galbraith will now lead its oncology R&D from initial discovery through late-stage development.

Galbraith had been leading AstraZeneca’s early-stage oncology R&D but will now also take on late-stage development responsibilities in cancer, joining...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

06 Jun 2025

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

29 May 2025

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

Executives On The Move: Capricor Therapeutics Acquires Chief Medical Officer From Pfizer, Galapagos And Cellarity Get A New CEO, And More

22 May 2025

Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

16 May 2025

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.